Fung, A T <br/><br/>
Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study).  [electronic resource] 

 -  Eye (London, England)  Sep 2012 
 - 1181-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5454 
<br/><br/><label>Standard No.: </label>10.1038/eye.2012.174  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Angiogenesis Inhibitors--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Female<br/>Humans<br/>Intravitreal Injections<br/>Male<br/>Pilot Projects<br/>Prospective Studies<br/>Ranibizumab<br/>Single-Blind Method<br/>Subretinal Fluid--metabolism<br/>Tomography, Optical Coherence<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>Visual Acuity--physiology<br/>Wet Macular Degeneration--diagnosis